Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients With Low- or Intermediate-Risk Localized Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial
JAMA Oncol 2022 Jun 16;[EPub Ahead of Print], ND Shore, J Renzulli, NE Fleshner, CMP Hollowell, S Vourganti, J Silberstein, R Siddiqui, J Hairston, D Elsouda, D Russell, MR Cooperberg, SA TomlinsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.